Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 475

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 475
---
 ​         ​   ​      (4,089)
​                                                                                                               ​   ​            ​            ​   ​             ​             ​   ​         ​         ​   ​            ​
Other movements                                                                                                 ​   ​            ​            ​   ​             ​             ​   ​         339       ​   ​          339
​                                                                                                               ​   ​            ​            ​   ​             ​             ​   ​         ​         ​   ​            ​
On December 31, 2024                                                                                            ​   €            —            ​   €             1,068,981     ​   €         2,371     ​   €    1,071,352
Of which current portion:                                                                                       ​   ​            —            ​   ​             230,105       ​   ​         2,371     ​   ​      232,476

(1)   The upfront received and the outstanding balance comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(2)   With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
We refer to note 2 for a detail of the allocation of the transaction price of our collaboration with Gilead and to note 5 and note 7 for a description of our revenue recognition.
28. Business combinations during the prior periods
On June 21, 2022 we acquired, in an all-cash transaction, 100% of the shares and voting interests of CellPoint for a total agreed payment at completion of €125 million, including consideration for other liabilities associated with the transaction amounting to €10.3 million. Additional contingent consideration up to €100.0 million is due when certain milestones would be achieved. ​
On the same date we acquired all of the outstanding capital of AboundBio, for a total agreed price of $14 million, including consideration for other liabilities associated with the transaction. ​

F-54

Details of the fair value of identifiable assets and liabilities acquired in both transactions, the purchase consideration, the goodwill at the acquisition date and the net cash outflow arising on acquisition are as follows:​

                                                    ​                                                       ​     ​        ​       ​     ​        ​       ​     ​        ​       ​     ​       ​     ​     ​       ​     ​     ​        ​      ​